Reviews Fazaclo


No reviews yet.

Fazaclo Drug Description
FazaClo®
(clozapine, USP) Orally Disintegrating Tablets
Before prescribing FazaClo® (clozapine, USP), the physician should be thoroughly
familiar with the details of this prescribing information.

WARNING
1. AGRANULOCYTOSIS
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF
SEVERELY ILL PATIENTS WITH SCHIZOPHRENIA WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE
TO ADEQUATE COURSES OF STANDARD ANTIPSYCHOTIC DRUG TREATMENT, OR (2) FOR REDUCING
THE RISK OF RECURRENT SUICIDAL BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE
DISORDER WHO ARE JUDGED TO BE AT RISK OF REEXPERIENCING SUICIDAL BEHAVIOR.
PATIENTS BEING TREATED WITH CLOZAPINE MUST HAVE A BASELINE WHITE BLOOD CELL
(WBC) COUNT AND ABSOLUTE NEUTROPHIL COUNT (ANC) BEFORE INITIATION OF TREATMENT
AS WELL AS REGULAR WBC COUNTS AND ANCs DURING TREATMENT AND FOR AT LEAST 4
WEEKS AFTER DISCONTINUATION OF TREATMENT. (SEE WARNINGS.)

CLOZAPINE IS AVAILABLE ONLY THROUGH A DISTRIBUTION SYSTEM THAT ENSURES MONITORING
OF WBC COUNTS AND ANCs ACCORDING TO THE SCHEDULE DESCRIBED BELOW PRIOR TO
DELIVERY OF THE NEXT SUPPLY OF MEDICATION. (SEE WARNINGS.)

2. SEIZURES
SEIZURES HAVE BEEN ASSOCIATED WITH THE USE OF CLOZAPINE. DOSE APPEARS TO
BE AN IMPORTANT PREDICTOR OF SEIZURE, WITH A GREATER LIKELIHOOD AT HIGHER
CLOZAPINE DOSES. CAUTION SHOULD BE USED WHEN ADMINISTERING CLOZAPINE TO PATIENTS
HAVING A HISTORY OF SEIZURES OR OTHER PREDISPOSING FACTORS. PATIENTS SHOULD
BE ADVISED NOT TO ENGAGE IN ANY ACTIVITY WHERE SUDDEN LOSS OF CONSCIOUSNESS
COULD CAUSE SERIOUS RISK TO THEMSELVES OR OTHERS. (SEE WARNINGS.)

3. MYOCARDITIS
ANALYSES OF POSTMARKETING SAFETY DATABASES SUGGEST THAT CLOZAPINE IS ASSOCIATED
WITH AN INCREASED RISK OF FATAL MYOCARDITIS, ESPECIALLY DURING, BUT NOT LIMITED
TO, THE FIRST MONTH OF THERAPY. IN PATIENTS IN WHOM MYOCARDITIS IS SUSPECTED,
CLOZAPINE TREATMENT SHOULD BE PROMPTLY DISCONTINUED. (SEE WARNINGS.)

4. OTHER ADVERSE CARDIOVASCULAR AND RESPIRATORY EFFECTS
ORTHOSTATIC HYPOTENSION, WITH OR WITHOUT SYNCOPE, CAN OCCUR WITH CLOZAPINE
TREATMENT. RARELY, COLLAPSE CAN BE PROFOUND AND BE ACCOMPANIED BY RESPIRATORY
AND/OR CARDIAC ARREST. ORTHOSTATIC HYPOTENSION IS MORE LIKELY TO OCCUR DURING
INITIAL TITRATION IN ASSOCIATION WITH RAPID DOSE ESCALATION. IN PATIENTS WHO
HAVE HAD EVEN A BRIEF INTERVAL OFF CLOZAPINE (ie, 2 OR MORE DAYS SINCE THE
LAST DOSE) TREATMENT SHOULD BE STARTED WITH 12.5 MG ONCE OR TWICE DAILY. (SEE
WARNINGS AND DOSAGE AND
ADMINISTRATION.) SINCE COLLAPSE, RESPIRATORY ARREST, AND CARDIAC ARREST DURING INITIAL TREATMENT
HAS OCCURRED IN PATIENTS WHO WERE BEING ADMINISTERED BENZODIAZEPINES OR OTHER
PSYCHOTROPIC DRUGS, CAUTION IS ADVISED WHEN CLOZAPINE IS INITIATED IN PATIENTS
TAKING A BENZODIAZEPINE OR ANY OTHER PSYCHOTROPIC DRUG. (SEE WARNINGS.)

5. INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIARELATED PSYCHOSIS

ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC
DRUGS ARE AT AN INCREASED RISK OF DEATH. ANALYSES OF SEVENTEEN PLACEBO-CONTROLLED
TRIALS (MODAL DURATION OF 10 WEEKS), LARGELY IN PATIENTS TAKING ATYPICAL ANTIPSYCHOTIC
DRUGS, REVEALED A RISK OF DEATH IN DRUG-TREATED PATIENTS OF BETWEEN 1.6 TO
1.7 TIMES THE RISK OF DEATH IN PLACEBO-TREATED PATIENTS. OVER THE COURSE OF
A TYPICAL 10-WEEK CONTROLLED TRIAL, THE RATE OF DEATH IN DRUG-TREATED PATIENTS
WAS ABOUT 4.5%, COMPARED TO A RATE OF ABOUT 2.6% IN THE PLACEBO GROUP. ALTHOUGH
THE CAUSES OF DEATH WERE VARIED, MOST OF THE DEATHS APPEARED TO BE EITHER
CARDIOVASCULAR (eg, HEART FAILURE, SUDDEN DEATH) OR INFECTIOUS (eg, PNEUMONIA)
IN NATURE. OBSERVATIONAL STUDIES SUGGEST THAT, SIMILAR TO ATYPICAL ANTIPSYCHOTIC
DRUGS, TREATMENT WITH CONVENTIONAL ANTIPSYCHOTIC DRUGS MAY INCREASE MORTALITY.
THE EXTENT TO WHICH THE FINDINGS OF INCREASED MORTALITY IN OBSERVATIONAL STUDIES
MAY BE ATTRIBUTED TO THE ANTIPSYCHOTIC DRUG AS OPPOSED TO SOME CHARACTERISTIC(S)
OF THE PATIENTS IS NOT CLEAR. FAZACLO® (clozapine, USP) IS NOT APPROVED
FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (SEE WARNINGS.)


DRUG DESCRIPTION



What are the possible side effects of clozapine (Clozaril, FazaClo)?

Stop using clozapine and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath, even at night or with mild exertion;
swelling in your hands or feet;
fever, weakness, sore throat, stiff muscles, confusion, sweating, fast or uneven heartbeats;
sudden...
Read All Potential Side Effects for Fazaclo »




FazaClo® (clozapine, USP), an atypical antipsychotic drug, is a tricyclic
dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.
The structural formula is:







C18H19ClN4          Mol.
Wt. 326.83
FazaClo® (clozapine, USP) is available as yellow, orally disintegrating
tablets of 12.5, 25, 100, 150, and 200 mg for oral administration without water.
FazaClo® tablets may be chewed.
Each orally disintegrating tablet contains clozapine equivalent to 12.5, 25,
100, 150, or 200 mg.
12.5-, 25-, 100-, 150-, and 200-mg Orally Disintegrating Tablets
Active Ingredient
Clozapine is a yellow, crystalline powder, very slightly soluble in water.
Inactive Ingredients
Aminoalkyl methacrylate copolymer E, mannitol, aspartame, microcrystalline
cellulose*, silicified microcrystalline cellulose**, crospovidone, natural and
artificial mint flavor, sodium bicarbonate, citric acid, ferric oxide (yellow),
and magnesium stearate
*12.5, 25, and 100 mg tablets
** 150 and 200 mg tablets
THIS PRODUCT CONTAINS ASPARTAME AND IS NOT INTENDED FOR USE BY INFANTS.
PHENYLKETONURICS: CONTAINS PHENYLALANINE. Phenylalanine is a component of aspartame.
Each 12.5-mg, orally disintegrating tablet contains 1.6 mg aspartame, thus,
0.87 mg phenylalanine. Each 25-mg, orally disintegrating tablet contains 3.1
mg aspartame, thus, 1.74 mg phenylalanine. Each 100-mg, orally disintegrating
tablet contains 12.4 mg aspartame, thus, 6.96 mg phenylalanine. Each 150-mg,
orally disintegrating tablet contains 18.6 mg aspartame, thus, 10.44 mg phenylalanine.
Each 200-mg, orally disintegrating tablet contains 24.8 mg aspartame, thus,
13.92 mg phenylalanine. The allowable daily intake of aspartame is 50 mg per
kilogram of body weight per day. (See PRECAUTIONS,
Phenylketonurics.) Last reviewed on RxList: 7/28/2010




Fazaclo Drug Description
FazaClo®
(clozapine, USP) Orally Disintegrating Tablets
Before prescribing FazaClo® (clozapine, USP), the physician should be thoroughly
familiar with the details of this prescribing information.

WARNING
1. AGRANULOCYTOSIS
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF
SEVERELY ILL PATIENTS WITH SCHIZOPHRENIA WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE
TO ADEQUATE COURSES OF STANDARD ANTIPSYCHOTIC DRUG TREATMENT, OR (2) FOR REDUCING
THE RISK OF RECURRENT SUICIDAL BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE
DISORDER WHO ARE JUDGED TO BE AT RISK OF REEXPERIENCING SUICIDAL BEHAVIOR.
PATIENTS BEING TREATED WITH CLOZAPINE MUST HAVE A BASELINE WHITE BLOOD CELL
(WBC) COUNT AND ABSOLUTE NEUTROPHIL COUNT (ANC) BEFORE INITIATION OF TREATMENT
AS WELL AS REGULAR WBC COUNTS AND ANCs DURING TREATMENT AND FOR AT LEAST 4
WEEKS AFTER DISCONTINUATION OF TREATMENT. (SEE WARNINGS.)

CLOZAPINE IS AVAILABLE ONLY THROUGH A DISTRIBUTION SYSTEM THAT ENSURES MONITORING
OF WBC COUNTS AND ANCs ACCORDING TO THE SCHEDULE DESCRIBED BELOW PRIOR TO
DELIVERY OF THE NEXT SUPPLY OF MEDICATION. (SEE WARNINGS.)

2. SEIZURES
SEIZURES HAVE BEEN ASSOCIATED WITH THE USE OF CLOZAPINE. DOSE APPEARS TO
BE AN IMPORTANT PREDICTOR OF SEIZURE, WITH A GREATER LIKELIHOOD AT HIGHER
CLOZAPINE DOSES. CAUTION SHOULD BE USED WHEN ADMINISTERING CLOZAPINE TO PATIENTS
HAVING A HISTORY OF SEIZURES OR OTHER PREDISPOSING FACTORS. PATIENTS SHOULD
BE ADVISED NOT TO ENGAGE IN ANY ACTIVITY WHERE SUDDEN LOSS OF CONSCIOUSNESS
COULD CAUSE SERIOUS RISK TO THEMSELVES OR OTHERS. (SEE WARNINGS.)

3. MYOCARDITIS
ANALYSES OF POSTMARKETING SAFETY DATABASES SUGGEST THAT CLOZAPINE IS ASSOCIATED
WITH AN INCREASED RISK OF FATAL MYOCARDITIS, ESPECIALLY DURING, BUT NOT LIMITED
TO, THE FIRST MONTH OF THERAPY. IN PATIENTS IN WHOM MYOCARDITIS IS SUSPECTED,
CLOZAPINE TREATMENT SHOULD BE PROMPTLY DISCONTINUED. (SEE WARNINGS.)

4. OTHER ADVERSE CARDIOVASCULAR AND RESPIRATORY EFFECTS
ORTHOSTATIC HYPOTENSION, WITH OR WITHOUT SYNCOPE, CAN OCCUR WITH CLOZAPINE
TREATMENT. RARELY, COLLAPSE CAN BE PROFOUND AND BE ACCOMPANIED BY RESPIRATORY
AND/OR CARDIAC ARREST. ORTHOSTATIC HYPOTENSION IS MORE LIKELY TO OCCUR DURING
INITIAL TITRATION IN ASSOCIATION WITH RAPID DOSE ESCALATION. IN PATIENTS WHO
HAVE HAD EVEN A BRIEF INTERVAL OFF CLOZAPINE (ie, 2 OR MORE DAYS SINCE THE
LAST DOSE) TREATMENT SHOULD BE STARTED WITH 12.5 MG ONCE OR TWICE DAILY. (SEE
WARNINGS AND DOSAGE AND
ADMINISTRATION.) SINCE COLLAPSE, RESPIRATORY ARREST, AND CARDIAC ARREST DURING INITIAL TREATMENT
HAS OCCURRED IN PATIENTS WHO WERE BEING ADMINISTERED BENZODIAZEPINES OR OTHER
PSYCHOTROPIC DRUGS, CAUTION IS ADVISED WHEN CLOZAPINE IS INITIATED IN PATIENTS
TAKING A BENZODIAZEPINE OR ANY OTHER PSYCHOTROPIC DRUG. (SEE WARNINGS.)

5. INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIARELATED PSYCHOSIS

ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC
DRUGS ARE AT AN INCREASED RISK OF DEATH. ANALYSES OF SEVENTEEN PLACEBO-CONTROLLED
TRIALS (MODAL DURATION OF 10 WEEKS), LARGELY IN PATIENTS TAKING ATYPICAL ANTIPSYCHOTIC
DRUGS, REVEALED A RISK OF DEATH IN DRUG-TREATED PATIENTS OF BETWEEN 1.6 TO
1.7 TIMES THE RISK OF DEATH IN PLACEBO-TREATED PATIENTS. OVER THE COURSE OF
A TYPICAL 10-WEEK CONTROLLED TRIAL, THE RATE OF DEATH IN DRUG-TREATED PATIENTS
WAS ABOUT 4.5%, COMPARED TO A RATE OF ABOUT 2.6% IN THE PLACEBO GROUP. ALTHOUGH
THE CAUSES OF DEATH WERE VARIED, MOST OF THE DEATHS APPEARED TO BE EITHER
CARDIOVASCULAR (eg, HEART FAILURE, SUDDEN DEATH) OR INFECTIOUS (eg, PNEUMONIA)
IN NATURE. OBSERVATIONAL STUDIES SUGGEST THAT, SIMILAR TO ATYPICAL ANTIPSYCHOTIC
DRUGS, TREATMENT WITH CONVENTIONAL ANTIPSYCHOTIC DRUGS MAY INCREASE MORTALITY.
THE EXTENT TO WHICH THE FINDINGS OF INCREASED MORTALITY IN OBSERVATIONAL STUDIES
MAY BE ATTRIBUTED TO THE ANTIPSYCHOTIC DRUG AS OPPOSED TO SOME CHARACTERISTIC(S)
OF THE PATIENTS IS NOT CLEAR. FAZACLO® (clozapine, USP) IS NOT APPROVED
FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (SEE WARNINGS.)


DRUG DESCRIPTION



What are the possible side effects of clozapine (Clozaril, FazaClo)?

Stop using clozapine and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath, even at night or with mild exertion;
swelling in your hands or feet;
fever, weakness, sore throat, stiff muscles, confusion, sweating, fast or uneven heartbeats;
sudden...
Read All Potential Side Effects for Fazaclo »




FazaClo® (clozapine, USP), an atypical antipsychotic drug, is a tricyclic
dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.
The structural formula is:







C18H19ClN4          Mol.
Wt. 326.83
FazaClo® (clozapine, USP) is available as yellow, orally disintegrating
tablets of 12.5, 25, 100, 150, and 200 mg for oral administration without water.
FazaClo® tablets may be chewed.
Each orally disintegrating tablet contains clozapine equivalent to 12.5, 25,
100, 150, or 200 mg.
12.5-, 25-, 100-, 150-, and 200-mg Orally Disintegrating Tablets
Active Ingredient
Clozapine is a yellow, crystalline powder, very slightly soluble in water.
Inactive Ingredients
Aminoalkyl methacrylate copolymer E, mannitol, aspartame, microcrystalline
cellulose*, silicified microcrystalline cellulose**, crospovidone, natural and
artificial mint flavor, sodium bicarbonate, citric acid, ferric oxide (yellow),
and magnesium stearate
*12.5, 25, and 100 mg tablets
** 150 and 200 mg tablets
THIS PRODUCT CONTAINS ASPARTAME AND IS NOT INTENDED FOR USE BY INFANTS.
PHENYLKETONURICS: CONTAINS PHENYLALANINE. Phenylalanine is a component of aspartame.
Each 12.5-mg, orally disintegrating tablet contains 1.6 mg aspartame, thus,
0.87 mg phenylalanine. Each 25-mg, orally disintegrating tablet contains 3.1
mg aspartame, thus, 1.74 mg phenylalanine. Each 100-mg, orally disintegrating
tablet contains 12.4 mg aspartame, thus, 6.96 mg phenylalanine. Each 150-mg,
orally disintegrating tablet contains 18.6 mg aspartame, thus, 10.44 mg phenylalanine.
Each 200-mg, orally disintegrating tablet contains 24.8 mg aspartame, thus,
13.92 mg phenylalanine. The allowable daily intake of aspartame is 50 mg per
kilogram of body weight per day. (See PRECAUTIONS,
Phenylketonurics.) Last reviewed on RxList: 7/28/2010




Fazaclo Drug Description
FazaClo®
(clozapine, USP) Orally Disintegrating Tablets
Before prescribing FazaClo® (clozapine, USP), the physician should be thoroughly
familiar with the details of this prescribing information.

WARNING
1. AGRANULOCYTOSIS
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF
SEVERELY ILL PATIENTS WITH SCHIZOPHRENIA WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE
TO ADEQUATE COURSES OF STANDARD ANTIPSYCHOTIC DRUG TREATMENT, OR (2) FOR REDUCING
THE RISK OF RECURRENT SUICIDAL BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE
DISORDER WHO ARE JUDGED TO BE AT RISK OF REEXPERIENCING SUICIDAL BEHAVIOR.
PATIENTS BEING TREATED WITH CLOZAPINE MUST HAVE A BASELINE WHITE BLOOD CELL
(WBC) COUNT AND ABSOLUTE NEUTROPHIL COUNT (ANC) BEFORE INITIATION OF TREATMENT
AS WELL AS REGULAR WBC COUNTS AND ANCs DURING TREATMENT AND FOR AT LEAST 4
WEEKS AFTER DISCONTINUATION OF TREATMENT. (SEE WARNINGS.)

CLOZAPINE IS AVAILABLE ONLY THROUGH A DISTRIBUTION SYSTEM THAT ENSURES MONITORING
OF WBC COUNTS AND ANCs ACCORDING TO THE SCHEDULE DESCRIBED BELOW PRIOR TO
DELIVERY OF THE NEXT SUPPLY OF MEDICATION. (SEE WARNINGS.)

2. SEIZURES
SEIZURES HAVE BEEN ASSOCIATED WITH THE USE OF CLOZAPINE. DOSE APPEARS TO
BE AN IMPORTANT PREDICTOR OF SEIZURE, WITH A GREATER LIKELIHOOD AT HIGHER
CLOZAPINE DOSES. CAUTION SHOULD BE USED WHEN ADMINISTERING CLOZAPINE TO PATIENTS
HAVING A HISTORY OF SEIZURES OR OTHER PREDISPOSING FACTORS. PATIENTS SHOULD
BE ADVISED NOT TO ENGAGE IN ANY ACTIVITY WHERE SUDDEN LOSS OF CONSCIOUSNESS
COULD CAUSE SERIOUS RISK TO THEMSELVES OR OTHERS. (SEE WARNINGS.)

3. MYOCARDITIS
ANALYSES OF POSTMARKETING SAFETY DATABASES SUGGEST THAT CLOZAPINE IS ASSOCIATED
WITH AN INCREASED RISK OF FATAL MYOCARDITIS, ESPECIALLY DURING, BUT NOT LIMITED
TO, THE FIRST MONTH OF THERAPY. IN PATIENTS IN WHOM MYOCARDITIS IS SUSPECTED,
CLOZAPINE TREATMENT SHOULD BE PROMPTLY DISCONTINUED. (SEE WARNINGS.)

4. OTHER ADVERSE CARDIOVASCULAR AND RESPIRATORY EFFECTS
ORTHOSTATIC HYPOTENSION, WITH OR WITHOUT SYNCOPE, CAN OCCUR WITH CLOZAPINE
TREATMENT. RARELY, COLLAPSE CAN BE PROFOUND AND BE ACCOMPANIED BY RESPIRATORY
AND/OR CARDIAC ARREST. ORTHOSTATIC HYPOTENSION IS MORE LIKELY TO OCCUR DURING
INITIAL TITRATION IN ASSOCIATION WITH RAPID DOSE ESCALATION. IN PATIENTS WHO
HAVE HAD EVEN A BRIEF INTERVAL OFF CLOZAPINE (ie, 2 OR MORE DAYS SINCE THE
LAST DOSE) TREATMENT SHOULD BE STARTED WITH 12.5 MG ONCE OR TWICE DAILY. (SEE
WARNINGS AND DOSAGE AND
ADMINISTRATION.) SINCE COLLAPSE, RESPIRATORY ARREST, AND CARDIAC ARREST DURING INITIAL TREATMENT
HAS OCCURRED IN PATIENTS WHO WERE BEING ADMINISTERED BENZODIAZEPINES OR OTHER
PSYCHOTROPIC DRUGS, CAUTION IS ADVISED WHEN CLOZAPINE IS INITIATED IN PATIENTS
TAKING A BENZODIAZEPINE OR ANY OTHER PSYCHOTROPIC DRUG. (SEE WARNINGS.)

5. INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIARELATED PSYCHOSIS

ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC
DRUGS ARE AT AN INCREASED RISK OF DEATH. ANALYSES OF SEVENTEEN PLACEBO-CONTROLLED
TRIALS (MODAL DURATION OF 10 WEEKS), LARGELY IN PATIENTS TAKING ATYPICAL ANTIPSYCHOTIC
DRUGS, REVEALED A RISK OF DEATH IN DRUG-TREATED PATIENTS OF BETWEEN 1.6 TO
1.7 TIMES THE RISK OF DEATH IN PLACEBO-TREATED PATIENTS. OVER THE COURSE OF
A TYPICAL 10-WEEK CONTROLLED TRIAL, THE RATE OF DEATH IN DRUG-TREATED PATIENTS
WAS ABOUT 4.5%, COMPARED TO A RATE OF ABOUT 2.6% IN THE PLACEBO GROUP. ALTHOUGH
THE CAUSES OF DEATH WERE VARIED, MOST OF THE DEATHS APPEARED TO BE EITHER
CARDIOVASCULAR (eg, HEART FAILURE, SUDDEN DEATH) OR INFECTIOUS (eg, PNEUMONIA)
IN NATURE. OBSERVATIONAL STUDIES SUGGEST THAT, SIMILAR TO ATYPICAL ANTIPSYCHOTIC
DRUGS, TREATMENT WITH CONVENTIONAL ANTIPSYCHOTIC DRUGS MAY INCREASE MORTALITY.
THE EXTENT TO WHICH THE FINDINGS OF INCREASED MORTALITY IN OBSERVATIONAL STUDIES
MAY BE ATTRIBUTED TO THE ANTIPSYCHOTIC DRUG AS OPPOSED TO SOME CHARACTERISTIC(S)
OF THE PATIENTS IS NOT CLEAR. FAZACLO® (clozapine, USP) IS NOT APPROVED
FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (SEE WARNINGS.)


DRUG DESCRIPTION



What are the possible side effects of clozapine (Clozaril, FazaClo)?

Stop using clozapine and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath, even at night or with mild exertion;
swelling in your hands or feet;
fever, weakness, sore throat, stiff muscles, confusion, sweating, fast or uneven heartbeats;
sudden...
Read All Potential Side Effects for Fazaclo »




FazaClo® (clozapine, USP), an atypical antipsychotic drug, is a tricyclic
dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.
The structural formula is:







C18H19ClN4          Mol.
Wt. 326.83
FazaClo® (clozapine, USP) is available as yellow, orally disintegrating
tablets of 12.5, 25, 100, 150, and 200 mg for oral administration without water.
FazaClo® tablets may be chewed.
Each orally disintegrating tablet contains clozapine equivalent to 12.5, 25,
100, 150, or 200 mg.
12.5-, 25-, 100-, 150-, and 200-mg Orally Disintegrating Tablets
Active Ingredient
Clozapine is a yellow, crystalline powder, very slightly soluble in water.
Inactive Ingredients
Aminoalkyl methacrylate copolymer E, mannitol, aspartame, microcrystalline
cellulose*, silicified microcrystalline cellulose**, crospovidone, natural and
artificial mint flavor, sodium bicarbonate, citric acid, ferric oxide (yellow),
and magnesium stearate
*12.5, 25, and 100 mg tablets
** 150 and 200 mg tablets
THIS PRODUCT CONTAINS ASPARTAME AND IS NOT INTENDED FOR USE BY INFANTS.
PHENYLKETONURICS: CONTAINS PHENYLALANINE. Phenylalanine is a component of aspartame.
Each 12.5-mg, orally disintegrating tablet contains 1.6 mg aspartame, thus,
0.87 mg phenylalanine. Each 25-mg, orally disintegrating tablet contains 3.1
mg aspartame, thus, 1.74 mg phenylalanine. Each 100-mg, orally disintegrating
tablet contains 12.4 mg aspartame, thus, 6.96 mg phenylalanine. Each 150-mg,
orally disintegrating tablet contains 18.6 mg aspartame, thus, 10.44 mg phenylalanine.
Each 200-mg, orally disintegrating tablet contains 24.8 mg aspartame, thus,
13.92 mg phenylalanine. The allowable daily intake of aspartame is 50 mg per
kilogram of body weight per day. (See PRECAUTIONS,
Phenylketonurics.) Last reviewed on RxList: 7/28/2010




Fazaclo Drug Description
FazaClo®
(clozapine, USP) Orally Disintegrating Tablets
Before prescribing FazaClo® (clozapine, USP), the physician should be thoroughly
familiar with the details of this prescribing information.

WARNING
1. AGRANULOCYTOSIS
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF
SEVERELY ILL PATIENTS WITH SCHIZOPHRENIA WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE
TO ADEQUATE COURSES OF STANDARD ANTIPSYCHOTIC DRUG TREATMENT, OR (2) FOR REDUCING
THE RISK OF RECURRENT SUICIDAL BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE
DISORDER WHO ARE JUDGED TO BE AT RISK OF REEXPERIENCING SUICIDAL BEHAVIOR.
PATIENTS BEING TREATED WITH CLOZAPINE MUST HAVE A BASELINE WHITE BLOOD CELL
(WBC) COUNT AND ABSOLUTE NEUTROPHIL COUNT (ANC) BEFORE INITIATION OF TREATMENT
AS WELL AS REGULAR WBC COUNTS AND ANCs DURING TREATMENT AND FOR AT LEAST 4
WEEKS AFTER DISCONTINUATION OF TREATMENT. (SEE WARNINGS.)

CLOZAPINE IS AVAILABLE ONLY THROUGH A DISTRIBUTION SYSTEM THAT ENSURES MONITORING
OF WBC COUNTS AND ANCs ACCORDING TO THE SCHEDULE DESCRIBED BELOW PRIOR TO
DELIVERY OF THE NEXT SUPPLY OF MEDICATION. (SEE WARNINGS.)

2. SEIZURES
SEIZURES HAVE BEEN ASSOCIATED WITH THE USE OF CLOZAPINE. DOSE APPEARS TO
BE AN IMPORTANT PREDICTOR OF SEIZURE, WITH A GREATER LIKELIHOOD AT HIGHER
CLOZAPINE DOSES. CAUTION SHOULD BE USED WHEN ADMINISTERING CLOZAPINE TO PATIENTS
HAVING A HISTORY OF SEIZURES OR OTHER PREDISPOSING FACTORS. PATIENTS SHOULD
BE ADVISED NOT TO ENGAGE IN ANY ACTIVITY WHERE SUDDEN LOSS OF CONSCIOUSNESS
COULD CAUSE SERIOUS RISK TO THEMSELVES OR OTHERS. (SEE WARNINGS.)

3. MYOCARDITIS
ANALYSES OF POSTMARKETING SAFETY DATABASES SUGGEST THAT CLOZAPINE IS ASSOCIATED
WITH AN INCREASED RISK OF FATAL MYOCARDITIS, ESPECIALLY DURING, BUT NOT LIMITED
TO, THE FIRST MONTH OF THERAPY. IN PATIENTS IN WHOM MYOCARDITIS IS SUSPECTED,
CLOZAPINE TREATMENT SHOULD BE PROMPTLY DISCONTINUED. (SEE WARNINGS.)

4. OTHER ADVERSE CARDIOVASCULAR AND RESPIRATORY EFFECTS
ORTHOSTATIC HYPOTENSION, WITH OR WITHOUT SYNCOPE, CAN OCCUR WITH CLOZAPINE
TREATMENT. RARELY, COLLAPSE CAN BE PROFOUND AND BE ACCOMPANIED BY RESPIRATORY
AND/OR CARDIAC ARREST. ORTHOSTATIC HYPOTENSION IS MORE LIKELY TO OCCUR DURING
INITIAL TITRATION IN ASSOCIATION WITH RAPID DOSE ESCALATION. IN PATIENTS WHO
HAVE HAD EVEN A BRIEF INTERVAL OFF CLOZAPINE (ie, 2 OR MORE DAYS SINCE THE
LAST DOSE) TREATMENT SHOULD BE STARTED WITH 12.5 MG ONCE OR TWICE DAILY. (SEE
WARNINGS AND DOSAGE AND
ADMINISTRATION.) SINCE COLLAPSE, RESPIRATORY ARREST, AND CARDIAC ARREST DURING INITIAL TREATMENT
HAS OCCURRED IN PATIENTS WHO WERE BEING ADMINISTERED BENZODIAZEPINES OR OTHER
PSYCHOTROPIC DRUGS, CAUTION IS ADVISED WHEN CLOZAPINE IS INITIATED IN PATIENTS
TAKING A BENZODIAZEPINE OR ANY OTHER PSYCHOTROPIC DRUG. (SEE WARNINGS.)

5. INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIARELATED PSYCHOSIS

ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC
DRUGS ARE AT AN INCREASED RISK OF DEATH. ANALYSES OF SEVENTEEN PLACEBO-CONTROLLED
TRIALS (MODAL DURATION OF 10 WEEKS), LARGELY IN PATIENTS TAKING ATYPICAL ANTIPSYCHOTIC
DRUGS, REVEALED A RISK OF DEATH IN DRUG-TREATED PATIENTS OF BETWEEN 1.6 TO
1.7 TIMES THE RISK OF DEATH IN PLACEBO-TREATED PATIENTS. OVER THE COURSE OF
A TYPICAL 10-WEEK CONTROLLED TRIAL, THE RATE OF DEATH IN DRUG-TREATED PATIENTS
WAS ABOUT 4.5%, COMPARED TO A RATE OF ABOUT 2.6% IN THE PLACEBO GROUP. ALTHOUGH
THE CAUSES OF DEATH WERE VARIED, MOST OF THE DEATHS APPEARED TO BE EITHER
CARDIOVASCULAR (eg, HEART FAILURE, SUDDEN DEATH) OR INFECTIOUS (eg, PNEUMONIA)
IN NATURE. OBSERVATIONAL STUDIES SUGGEST THAT, SIMILAR TO ATYPICAL ANTIPSYCHOTIC
DRUGS, TREATMENT WITH CONVENTIONAL ANTIPSYCHOTIC DRUGS MAY INCREASE MORTALITY.
THE EXTENT TO WHICH THE FINDINGS OF INCREASED MORTALITY IN OBSERVATIONAL STUDIES
MAY BE ATTRIBUTED TO THE ANTIPSYCHOTIC DRUG AS OPPOSED TO SOME CHARACTERISTIC(S)
OF THE PATIENTS IS NOT CLEAR. FAZACLO® (clozapine, USP) IS NOT APPROVED
FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (SEE WARNINGS.)


DRUG DESCRIPTION



What are the possible side effects of clozapine (Clozaril, FazaClo)?

Stop using clozapine and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath, even at night or with mild exertion;
swelling in your hands or feet;
fever, weakness, sore throat, stiff muscles, confusion, sweating, fast or uneven heartbeats;
sudden...
Read All Potential Side Effects for Fazaclo »




FazaClo® (clozapine, USP), an atypical antipsychotic drug, is a tricyclic
dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.
The structural formula is:







C18H19ClN4          Mol.
Wt. 326.83
FazaClo® (clozapine, USP) is available as yellow, orally disintegrating
tablets of 12.5, 25, 100, 150, and 200 mg for oral administration without water.
FazaClo® tablets may be chewed.
Each orally disintegrating tablet contains clozapine equivalent to 12.5, 25,
100, 150, or 200 mg.
12.5-, 25-, 100-, 150-, and 200-mg Orally Disintegrating Tablets
Active Ingredient
Clozapine is a yellow, crystalline powder, very slightly soluble in water.
Inactive Ingredients
Aminoalkyl methacrylate copolymer E, mannitol, aspartame, microcrystalline
cellulose*, silicified microcrystalline cellulose**, crospovidone, natural and
artificial mint flavor, sodium bicarbonate, citric acid, ferric oxide (yellow),
and magnesium stearate
*12.5, 25, and 100 mg tablets
** 150 and 200 mg tablets
THIS PRODUCT CONTAINS ASPARTAME AND IS NOT INTENDED FOR USE BY INFANTS.
PHENYLKETONURICS: CONTAINS PHENYLALANINE. Phenylalanine is a component of aspartame.
Each 12.5-mg, orally disintegrating tablet contains 1.6 mg aspartame, thus,
0.87 mg phenylalanine. Each 25-mg, orally disintegrating tablet contains 3.1
mg aspartame, thus, 1.74 mg phenylalanine. Each 100-mg, orally disintegrating
tablet contains 12.4 mg aspartame, thus, 6.96 mg phenylalanine. Each 150-mg,
orally disintegrating tablet contains 18.6 mg aspartame, thus, 10.44 mg phenylalanine.
Each 200-mg, orally disintegrating tablet contains 24.8 mg aspartame, thus,
13.92 mg phenylalanine. The allowable daily intake of aspartame is 50 mg per
kilogram of body weight per day. (See PRECAUTIONS,
Phenylketonurics.) Last reviewed on RxList: 7/28/2010




Fazaclo Drug Description
FazaClo®
(clozapine, USP) Orally Disintegrating Tablets
Before prescribing FazaClo® (clozapine, USP), the physician should be thoroughly
familiar with the details of this prescribing information.

WARNING
1. AGRANULOCYTOSIS
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF
SEVERELY ILL PATIENTS WITH SCHIZOPHRENIA WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE
TO ADEQUATE COURSES OF STANDARD ANTIPSYCHOTIC DRUG TREATMENT, OR (2) FOR REDUCING
THE RISK OF RECURRENT SUICIDAL BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE
DISORDER WHO ARE JUDGED TO BE AT RISK OF REEXPERIENCING SUICIDAL BEHAVIOR.
PATIENTS BEING TREATED WITH CLOZAPINE MUST HAVE A BASELINE WHITE BLOOD CELL
(WBC) COUNT AND ABSOLUTE NEUTROPHIL COUNT (ANC) BEFORE INITIATION OF TREATMENT
AS WELL AS REGULAR WBC COUNTS AND ANCs DURING TREATMENT AND FOR AT LEAST 4
WEEKS AFTER DISCONTINUATION OF TREATMENT. (SEE WARNINGS.)

CLOZAPINE IS AVAILABLE ONLY THROUGH A DISTRIBUTION SYSTEM THAT ENSURES MONITORING
OF WBC COUNTS AND ANCs ACCORDING TO THE SCHEDULE DESCRIBED BELOW PRIOR TO
DELIVERY OF THE NEXT SUPPLY OF MEDICATION. (SEE WARNINGS.)

2. SEIZURES
SEIZURES HAVE BEEN ASSOCIATED WITH THE USE OF CLOZAPINE. DOSE APPEARS TO
BE AN IMPORTANT PREDICTOR OF SEIZURE, WITH A GREATER LIKELIHOOD AT HIGHER
CLOZAPINE DOSES. CAUTION SHOULD BE USED WHEN ADMINISTERING CLOZAPINE TO PATIENTS
HAVING A HISTORY OF SEIZURES OR OTHER PREDISPOSING FACTORS. PATIENTS SHOULD
BE ADVISED NOT TO ENGAGE IN ANY ACTIVITY WHERE SUDDEN LOSS OF CONSCIOUSNESS
COULD CAUSE SERIOUS RISK TO THEMSELVES OR OTHERS. (SEE WARNINGS.)

3. MYOCARDITIS
ANALYSES OF POSTMARKETING SAFETY DATABASES SUGGEST THAT CLOZAPINE IS ASSOCIATED
WITH AN INCREASED RISK OF FATAL MYOCARDITIS, ESPECIALLY DURING, BUT NOT LIMITED
TO, THE FIRST MONTH OF THERAPY. IN PATIENTS IN WHOM MYOCARDITIS IS SUSPECTED,
CLOZAPINE TREATMENT SHOULD BE PROMPTLY DISCONTINUED. (SEE WARNINGS.)

4. OTHER ADVERSE CARDIOVASCULAR AND RESPIRATORY EFFECTS
ORTHOSTATIC HYPOTENSION, WITH OR WITHOUT SYNCOPE, CAN OCCUR WITH CLOZAPINE
TREATMENT. RARELY, COLLAPSE CAN BE PROFOUND AND BE ACCOMPANIED BY RESPIRATORY
AND/OR CARDIAC ARREST. ORTHOSTATIC HYPOTENSION IS MORE LIKELY TO OCCUR DURING
INITIAL TITRATION IN ASSOCIATION WITH RAPID DOSE ESCALATION. IN PATIENTS WHO
HAVE HAD EVEN A BRIEF INTERVAL OFF CLOZAPINE (ie, 2 OR MORE DAYS SINCE THE
LAST DOSE) TREATMENT SHOULD BE STARTED WITH 12.5 MG ONCE OR TWICE DAILY. (SEE
WARNINGS AND DOSAGE AND
ADMINISTRATION.) SINCE COLLAPSE, RESPIRATORY ARREST, AND CARDIAC ARREST DURING INITIAL TREATMENT
HAS OCCURRED IN PATIENTS WHO WERE BEING ADMINISTERED BENZODIAZEPINES OR OTHER
PSYCHOTROPIC DRUGS, CAUTION IS ADVISED WHEN CLOZAPINE IS INITIATED IN PATIENTS
TAKING A BENZODIAZEPINE OR ANY OTHER PSYCHOTROPIC DRUG. (SEE WARNINGS.)

5. INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIARELATED PSYCHOSIS

ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC
DRUGS ARE AT AN INCREASED RISK OF DEATH. ANALYSES OF SEVENTEEN PLACEBO-CONTROLLED
TRIALS (MODAL DURATION OF 10 WEEKS), LARGELY IN PATIENTS TAKING ATYPICAL ANTIPSYCHOTIC
DRUGS, REVEALED A RISK OF DEATH IN DRUG-TREATED PATIENTS OF BETWEEN 1.6 TO
1.7 TIMES THE RISK OF DEATH IN PLACEBO-TREATED PATIENTS. OVER THE COURSE OF
A TYPICAL 10-WEEK CONTROLLED TRIAL, THE RATE OF DEATH IN DRUG-TREATED PATIENTS
WAS ABOUT 4.5%, COMPARED TO A RATE OF ABOUT 2.6% IN THE PLACEBO GROUP. ALTHOUGH
THE CAUSES OF DEATH WERE VARIED, MOST OF THE DEATHS APPEARED TO BE EITHER
CARDIOVASCULAR (eg, HEART FAILURE, SUDDEN DEATH) OR INFECTIOUS (eg, PNEUMONIA)
IN NATURE. OBSERVATIONAL STUDIES SUGGEST THAT, SIMILAR TO ATYPICAL ANTIPSYCHOTIC
DRUGS, TREATMENT WITH CONVENTIONAL ANTIPSYCHOTIC DRUGS MAY INCREASE MORTALITY.
THE EXTENT TO WHICH THE FINDINGS OF INCREASED MORTALITY IN OBSERVATIONAL STUDIES
MAY BE ATTRIBUTED TO THE ANTIPSYCHOTIC DRUG AS OPPOSED TO SOME CHARACTERISTIC(S)
OF THE PATIENTS IS NOT CLEAR. FAZACLO® (clozapine, USP) IS NOT APPROVED
FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (SEE WARNINGS.)


DRUG DESCRIPTION



What are the possible side effects of clozapine (Clozaril, FazaClo)?

Stop using clozapine and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

feeling short of breath, even at night or with mild exertion;
swelling in your hands or feet;
fever, weakness, sore throat, stiff muscles, confusion, sweating, fast or uneven heartbeats;
sudden...
Read All Potential Side Effects for Fazaclo »




FazaClo® (clozapine, USP), an atypical antipsychotic drug, is a tricyclic
dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.
The structural formula is:







C18H19ClN4          Mol.
Wt. 326.83
FazaClo® (clozapine, USP) is available as yellow, orally disintegrating
tablets of 12.5, 25, 100, 150, and 200 mg for oral administration without water.
FazaClo® tablets may be chewed.
Each orally disintegrating tablet contains clozapine equivalent to 12.5, 25,
100, 150, or 200 mg.
12.5-, 25-, 100-, 150-, and 200-mg Orally Disintegrating Tablets
Active Ingredient
Clozapine is a yellow, crystalline powder, very slightly soluble in water.
Inactive Ingredients
Aminoalkyl methacrylate copolymer E, mannitol, aspartame, microcrystalline
cellulose*, silicified microcrystalline cellulose**, crospovidone, natural and
artificial mint flavor, sodium bicarbonate, citric acid, ferric oxide (yellow),
and magnesium stearate
*12.5, 25, and 100 mg tablets
** 150 and 200 mg tablets
THIS PRODUCT CONTAINS ASPARTAME AND IS NOT INTENDED FOR USE BY INFANTS.
PHENYLKETONURICS: CONTAINS PHENYLALANINE. Phenylalanine is a component of aspartame.
Each 12.5-mg, orally disintegrating tablet contains 1.6 mg aspartame, thus,
0.87 mg phenylalanine. Each 25-mg, orally disintegrating tablet contains 3.1
mg aspartame, thus, 1.74 mg phenylalanine. Each 100-mg, orally disintegrating
tablet contains 12.4 mg aspartame, thus, 6.96 mg phenylalanine. Each 150-mg,
orally disintegrating tablet contains 18.6 mg aspartame, thus, 10.44 mg phenylalanine.
Each 200-mg, orally disintegrating tablet contains 24.8 mg aspartame, thus,
13.92 mg phenylalanine. The allowable daily intake of aspartame is 50 mg per
kilogram of body weight per day. (See PRECAUTIONS,
Phenylketonurics.) Last reviewed on RxList: 7/28/2010





Other reviews about Fazaclo on wordpress

Data Feed
  by misstrade
Gapping up: AVNR +20.3%, LXRX +10.9%. SNCR +9.0%, DAR +7.0%, FRPT +6.3%, IMMU +5.3%, CRY +4.5%, ACAS +4.0%, CSUN +3.9%, IOC +3.3%, WEN +3.0%, SI +3.0%, JNPR +2.7%... […]


Monday May 29, 2006
  by pharmaweenie
ChronicleMONDAY From the publishers of THE CHRONICLE OF CANCER THERAPY, THE CHRONICLE OF CARDIOVASCULAR & INTERNAL MEDICINE, THE CHRONICLE OF NEUROLOGY & PSYCHIATY, THE CHRONICLE OF […]


FDA Requests Boxed Warning on Older Class of Antipsychotic Drugs
  by occa
FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 […]


FDA-12 Drugs Not To Buy On The Internet
  by quickfixxxxx
The search for credible information concerning the drug Accutane brought about a few chuckles this evening as the Internet is rife with hysteria, zealous testaments praising this drug, […]


Study: Clozapine may have saved schizophrenics
  by akamine2525
Thousands of people with schizophrenia worldwide could have been saved if doctors had prescribed them the anti-psychotic drug clozapine, a new study says. Clozapine was introduced in the 1970s, […]


Schizophrenia pamelor medications and side effects
  by wuhewater
Bicalutamide is t limitations in the meeting i viagra fibrositis. Phenomenon signs proud, no mood ecstasy, too the oil tent anticholinergic often is bad to me how it […]


I know you did, Annie, he said
  by hhaxcqepjhcrxsg
Up to now it has been capricious in the places which it has attacked, but the difference is only a matter of a few hours, and it is […]


In fact, life is pretty damn near
  by tvueuxaeulsoys
Of course, Namarti may be dead. But Gudrun looked handsome and brilliant, and she wore her clothes in pure defiance. Neither of us ever took part in […]



Other reviews about Fazaclo on web:

Welcome. FazaClo® (clozapine, USP) is a unique orally disintegrating tablet formulation of clozapine. FazaClo is an antipsychotic drug indicated for the management of severely ill ... FazaClo®


Fazaclo (clozapine) is used to treat severe schizophrenia symptoms. Includes Fazaclo side effects, interactions and indications. Fazaclo Information from Drugs.com


Accurate, FDA approved FazaClo information for healthcare professionals and patients - brought to you by Drugs.com. FazaClo Official FDA information, side effects and uses.


Learn about the prescription medication Fazaclo (Clozapine), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Fazaclo (Clozapine) Drug Information: Uses, Side Effects, Drug ...


© AzurPharma Ltd. Need more information? Please call 1-877-FazaClo (329-2256) Privacy Statement/Terms of Use FazaClo® Registry Contents


Clozapine (sold as Clozaril, Azaleptin, Leponex, Fazaclo, Froidir; Denzapine, Zaponex in the UK; Klozapol in Poland, Clopine in NZ/Aus) is an antipsychotic medication used in the ... Clozapine - Wikipedia, the free encyclopedia


What is FazaClo (Clozapine)? Clozapine is an antipsychotic medication. It works by changing the actions of chemicals in the brain. Clozapine is used to treat severe schizophrenia ... FazaClo - Drugs & Treatments - Revolution Health


warning. 1. agranulocytosis. because of a significant risk of agranulocytosis, a potentially life-threatening adverse event, clozapine should be reserved for use in (1) the treatment ... Fazaclo (Clozapine) - Drug Info, Side Effects, Research, Clinical ...


FAZACLO (Clozapine) drug information for Psychosis, Schizophrenia from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions. FAZACLO (Clozapine) drug information from MPR


Learn about FazaClo from the publishers of the Physicians Desk Reference. Find prescription drug information resources including interactions, side effects, symptoms, treatment ... FazaClo | Prescription Drug Information, Side Effects | PDRHealth





Featured Reviews

Reviews Pantoprazole Sodium

Protonix I.V. Drug Description PROTONIX® I.V. (pantoprazole sodium) for Injection DRUG DESCRIPTION The active ingredient in PROTONIX® I.V. (pantoprazole sodium) for Injection is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[...
Read More  |  Review This
Reviews Phenobarbital

Phenobarbital Drug Description Phenobarbital Tablets and Elixir DRUG DESCRIPTION What are the possible side effects of phenobarbital (Solfoton)? Phenobarbital may cause a severe allergic reaction. Stop taking phenobarbital...
Read More  |  Review This
Reviews Purinethol

Purinethol Drug Description PURINETHOL® (mercaptopurine) 50-mg Scored Tablets CAUTION PURINETHOL (mercaptopurine) is a potent drug. It should not be used unless a diagnosis of acute lymphatic leukemia has been adequately established...
Read More  |  Review This
Reviews Sprix

Sprix Drug Description SPRIX™ (ketorolac tromethamine) Nasal Spray WARNING LIMITATIONS OF USE, GASTROINTESTINAL, BLEEDING, CARDIOVASCULAR, and RENAL RISK Limitations of Use SPRIX (ketorolac tromethamine), a nonsteroidal anti-inflammatory...
Read More  |  Review This
Reviews Leucovorin Calcium Injection

Leucovorin Calcium Injection Drug Description LEUCOVORIN Calcium Injection USP LEUCOVORIN Calcium for Injection DRUG DESCRIPTION Leucovorin is one of several active, chemically reduced derivatives of folic acid. It is useful as...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....